Figure 7.

Anti-metastatic effect of the H-RT and L-TBI combination therapy. (A) Comparison of representative H&E-stained in lung tissue sections at 24 days after 4T1 cells implantation (original magnification × 100). The arrows point to the metastatic infiltration. (B) Representative macroscopic images of the lungs in different groups. The arrows point to the metastatic nodules in the lung (n = 5 mice/group). (C) Comparison of the lung metastatic nodules between control, L-TBI, H-RT, and H-RT+L-TBI group (n = 5 mice/group). (D) Frequency of IFN-γ⁺ CD8⁺ T cells (CD3⁺CD8⁺IFN-γ⁺), G-MDSC (CD45⁺CD11c⁻CD11b⁺Ly6G⁺Ly6c^low), M-MDSC (CD45⁺CD11c⁻CD11b⁺Ly6G⁻Ly6c^hi), M1 (CD45⁺CD11b⁺F4/80⁺CD206⁻), M2 (CD45⁺CD11b⁺F4/80⁺CD206⁺), and Eosinophils (CD45⁺Siglec-F⁺Gr1^low) in mice spleens (n = 6 mice/group). Data are representative charts or the percentages of individual subjects. Data are expressed as mean ± SE. In general, combined therapy of H-RT+L-TBI significantly reduced the number and diameter of lung metastatic nodules (P < 0.001). (^*P < 0.05, ^**P < 0.01, ^***P < 0.001, NS = not significant).